Martin Shkreli, the "pharma bro" in prison for defrauding investors, faces a lawsuit filed by the Federal Trade Commission and New York attorney general's office for an alleged scheme to preserve his monopoly for the drug Daraprim, whose price increased by more than 4,000% in one day.